title: How the FDA forgot the evidence: the case of donepezil 23 mg.
authors.affiliation: VA Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vermont 05009, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Schwartz
authors.forename: Steven
authors.initials: S
authors.lastname: Woloshin
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D000077265:Donepezil; D017277:Drug Approval; D004348:Drug Labeling / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D007189:Indans / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D040541:Marketing / Q000379:methods; D018697:Nootropic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil